​

BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BCRX Stock Forecast

BioCryst Pharmaceuticals (BCRX) stock forecast, based on 28 Wall Street analysts, predicts a 12-month average price target of $12.67, with a high of $15.00 and a low of $8.00. This represents a 73.32% increase from the last price of $7.31.

- $3 $6 $9 $12 $15 High: $15 Avg: $12.67 Low: $8 Last Closed Price: $7.31

BCRX Stock Rating

BioCryst Pharmaceuticals stock's rating consensus is Buy, based on 28 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (85.71%), 4 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 28 0 4 24 Strong Sell Sell Hold Buy Strong Buy

BCRX Price Target Upside V Benchmarks

TypeNameUpside
StockBioCryst Pharmaceuticals73.32%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts333
Avg Price Target$12.67$12.67$12.67
Last Closing Price$7.31$7.31$7.31
Upside/Downside73.32%73.32%73.32%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25542--11
Sep, 25551--11
Aug, 25551--11
Jul, 25441--9
Jun, 25551--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2025RBC Capital$15.00$6.42133.64%105.20%
Oct 14, 2025Maury RaycroftJefferies$15.00$6.42133.64%105.20%
Oct 01, 2025Evercore ISI$8.00$7.2410.50%9.44%
Aug 06, 2024Gena WangBarclays$7.00$7.51-6.79%-4.24%
Aug 05, 2024Maury RaycroftJefferies$11.00$7.5146.47%50.48%
Nov 02, 2022Liisa BaykoEvercore ISI$16.00$12.3929.14%118.88%
Aug 23, 2022Gena WangBarclays$14.00$14.33-2.30%91.52%
Jan 10, 2022Ken CacciatoreCowen & Co.$25.00$14.7869.15%242.00%
Nov 03, 2021Brian ChengCantor Fitzgerald$21.00$12.4069.35%187.28%
Aug 09, 2021Maury RaycroftJefferies$19.00$17.657.65%159.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2025Cantor FitzgeraldOverweightOverweighthold
Oct 15, 2025CitigroupOutperformOutperformhold
Oct 14, 2025RBC CapitalOutperformOutperformhold
Oct 14, 2025JefferiesBuyBuyhold
May 06, 2025RBC CapitalOutperformOutperformhold
Nov 04, 2024Piper SandlerOverweightOverweighthold
Nov 04, 2024Bank of America SecuritiesBuyBuyhold
Aug 06, 2024JMP SecuritiesOutperformOutperformhold
Aug 06, 2024BarclaysEqual-WeightEqual-Weighthold
Aug 05, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.18$-1.03$-1.33$-1.18$-0.43----
Avg Forecast$-1.00$-1.22$-1.11$-1.05$-0.37$-0.09$0.27$0.74$0.97
High Forecast$-0.90$-1.10$-1.05$-0.98$-0.29$0.16$0.38$1.17$0.98
Low Forecast$-1.06$-1.29$-1.15$-1.23$-0.42$-0.32$0.13$0.25$0.95
Surprise %18.00%-15.57%19.82%12.38%16.22%----

Revenue Forecast

$0 $170M $340M $510M $680M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$17.81M$157.17M$270.83M$331.41M$450.71M----
Avg Forecast$28.56M$160.40M$265.41M$327.97M$449.34M$548.90M$628.83M$725.85M$810.41M
High Forecast$29.85M$167.64M$271.98M$333.03M$452.05M$551.10M$628.84M$730.83M$818.52M
Low Forecast$26.44M$148.50M$253.42M$325.16M$447.13M$547.52M$628.83M$720.86M$801.33M
Surprise %-37.63%-2.01%2.04%1.05%0.30%----

Net Income Forecast

$-300M $-190M $-80M $30M $140M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-196.57M$-184.06M$-247.12M$-226.54M$-88.88M----
Avg Forecast$-160.74M$-161.72M$-213.98M$-226.54M$-68.56M$-13.73M$49.07M$212.79M$185.47M
High Forecast$-128.59M$-129.37M$-201.42M$-181.23M$-55.59M$30.75M$73.83M$225.13M$187.88M
Low Forecast$-192.88M$-194.06M$-220.87M$-271.85M$-81.53M$-61.50M$24.30M$47.93M$182.77M
Surprise %22.29%13.82%15.49%-29.64%----

BCRX Forecast FAQ

Is BioCryst Pharmaceuticals stock a buy?

BioCryst Pharmaceuticals stock has a consensus rating of Buy, based on 28 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioCryst Pharmaceuticals is a favorable investment for most analysts.

What is BioCryst Pharmaceuticals's price target?

BioCryst Pharmaceuticals's price target, set by 28 Wall Street analysts, averages $12.67 over the next 12 months. The price target range spans from $8 at the low end to $15 at the high end, suggesting a potential 73.32% change from the previous closing price of $7.31.

How does BioCryst Pharmaceuticals stock forecast compare to its benchmarks?

BioCryst Pharmaceuticals's stock forecast shows a 73.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioCryst Pharmaceuticals over the past three months?

  • October 2025: 45.45% Strong Buy, 36.36% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 45.45% Strong Buy, 45.45% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 45.45% Strong Buy, 45.45% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is BioCryst Pharmaceuticals’s EPS forecast?

BioCryst Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.09, marking a -79.07% decrease from the reported $-0.43 in 2024. Estimates for the following years are $0.27 in 2026, $0.74 in 2027, and $0.97 in 2028.

What is BioCryst Pharmaceuticals’s revenue forecast?

BioCryst Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $548.9M, reflecting a 21.79% increase from the reported $450.71M in 2024. The forecast for 2026 is $628.83M, followed by $725.85M for 2027, and $810.41M for 2028.

What is BioCryst Pharmaceuticals’s net income forecast?

BioCryst Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-13.728M, representing a -84.55% decrease from the reported $-88.881M in 2024. Projections indicate $49.07M in 2026, $212.79M in 2027, and $185.47M in 2028.